|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Performance Assessment of Pharmaceutical Company- A Case Study on Sun Pharmaceutical Industries Ltd. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Paper Id :
16930 Submission Date :
2022-12-05 Acceptance Date :
2022-12-16 Publication Date :
2022-12-25
This is an open-access research paper/article distributed under the terms of the Creative Commons Attribution 4.0 International, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For verification of this paper, please visit on
http://www.socialresearchfoundation.com/remarking.php#8
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abstract |
Sun pharmaceutical industries Ltd. is largest pharma company in India and the fourth largest generic pharmaceutical company in the world. The objective of this study is to assess the overall financial performance of the Sun Pharma Ltd. From the analysis of financial performance of Sun Pharma Ltd. through ratio analysis over the study period 2016-17 to 2020-21 it is found that all the liquidity, profitability (except-2021), efficiency ratios had gradually improved over the study period; but operating cash flow position to be improved by reduction of non operating expenses, collection efficiency to be improved and company can take cheaper debt capital facility to improve earnings per share.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Keywords | Financial Performance, Ratio Analysis, Factor Analysis, Pharmaceutical, Principal Component Analysis, Sun Pharmaceutical. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Introduction |
India is the largest supplier of generic drugs in the world. India's pharmaceutical sector supplies more than 50% of the global demand for various vaccines, 40% of the general demand in the US and 25% of all medicines in the UK. Globally, India ranks 3rd in pharmaceutical production by volume and 14th in value. The national pharmaceutical industry consists of a network of 3,000 pharmaceutical companies and about 10,500 manufacturing units. India occupies an important position in the world pharmaceutical industry.
There are many firms which contributed in the success of Indian pharmaceutical industry and among them Sun Pharmaceutical Ltd. hold an important position. Sun pharmaceutical industries Ltd. is largest pharma company in India and the fourth largest generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion. Over 72% of Sun Pharma's sales come from markets outside of India, primarily the United States. The United States is the largest market, accounting for about 30% of the company's revenue. Production is spread across 44 global locations in India, USA, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generic drugs, with a robust pipeline awaiting approval from the Food and Drug Administration (FDA). It was started in the year 1983 and since then it acquired many pharma companies.
The company acquired a large stake in Taro Pharmaceuticals in 2010, which is amongst the largest generic companies in US and currently it holds about 69% stake in Taro Pharmaceuticals. In 2012, Sun Pharma again announced acquisition of two more US based companies- DUSA Pharmaceuticals and URL pharma. In 2014, it acquired Ranbaxy in US $4 billion which made Sun Pharma the world’s fifth largest pharmaceutical company. Its most recent acquisition is of Polo Pharma in Japan so that it can strengthen its global dermatology presence.
The segments Sun Pharma targeted are dermatology, ophthalmology and oncology. Currently it deals with over 2000 products in over 100 countries.
Financial statement analysis is the process of reviewing and analyzing the financial statements of a business in order to make better economic decisions to generate future income. These reports include the income statement, balance sheet, cash flow statement, notes to accounts, and statement of changes in equity. To assess the financial performance of Sun Pharmaceuticals Ltd. various ratios have been taken into consideration to assess firm’s liquidity, leverage, growth, margins, profitability, rates of return, valuation and more.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Objective of study | The objective of this study is to assess the overall financial performance of the Sun Pharma Ltd. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review of Literature | To assess the financial performances of Pharmaceutical
companies few literatures were reviewed. Bhunia,A. (2010) concluded
that liquidity position of KAPL and RDPL was quite strong and the predicted
that Indian pharma industry would witness an increase in market share. Sheela,
C.S. & Karthikeyan, K. (2012) showed the impact and value of
DuPont model drivers on return on equity. The study compared the financial
performance of top three companies which are Cipla, Ranbaxy and Dr Reddy’s Lab
and found that Cipla had highest return on equity which was done by reducing
its expenses and cost. Altaf, N. & Ahmad, F. (2019) discussed
about working capital financing and its relation with financial performance and
found that it is guided by inverted U-shaped curve. Priyadharshini & Rajeshwari (2021) analysed profitability
and liquidity of Sun Pharma and Divi’s Laboratories to reveal that the
companies were performing well but there was a scope of growth in the
industry. Panigrahi, Ashok (2019) analysed financial performance
by studying the relationship between profitability ratios of five
leading pharma companies and found a significant relation between them.
However, the study focused mainly on profitability only for performance
analysis. From the above literature review it is found that most of
the articles had used ratio analysis tool to assess the financial health and
the following points were came into picture 1. Some articles had showed the relationship between
leverage and profitability of a firm. 2. Some articles had studied how liquidity and solvency
ratios influence profitability. 3. Some articles assessed the performance of the
companies based on DuPont analysis. 4. Some articles studied the dependence of profitability
on working capital. Research Gap 1. Most of the studies showed dependence of working capital or leverage only on the profitability but has not assessed the overall performance of the firm. 2. Further the studies had not done Principal Component analysis to find out leading ratios which had influenced liquidity, profitability, efficiency and Capital structure of the company. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Methodology | The study is done mainly relative measurement technique. Ratio analysis has been done by analysing liquidity, profitability, efficiency, leverage and market value analysis.
Principal Component analysis is done because all these factors with their constituent ratios are not equally important in determining performance of the selected company, someone of these factors may be more important than others in the sense of its explaining power or predictive power. Further, all the ratios may not move in the same direction to derive the valid conclusion. An attempt is made to club the homogeneous ratios in the form of liquidity, profitability, efficiency, leverage and market value ratio then a regression equation is done with gross-profit dependent variable to assess the performance of the company. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Analysis | Findings: From the analysis of
financial performance of Sun Pharma Ltd. through ratio analysis over the study
period 2016-17 to 2020-21 it is found that all the liquidity ratios
have gradually improved over the study period; but in each year they are below
the standard norm except quick ratio in last year (see Table-1). This implies
that Sun Pharma has taken aggressive policy in liquidity management to maximize
its profitability. Table-1: Liquidity Analysis
Table-2: Principal Component analysis of Liquidity
Position
Further form principal component analysis of three
liquidity ratios, it is found that as per Kaiser criterion (KMO.726) the
principal factor is current ratio, because Eigen value is more than 1. From
Bartlet Test of Sphericity (BTO) it is found that BTO=12.61 and it is
significant at 1% probability level, which implies Principal Component Analysis
is well fitted here Again, from regression analysis it is found that operating
profit and liquidity are negatively related, though it is insignificant. Profitability Analysis: In
profitability analysis I have used three ratios namely gross margin, operating
margin and net profit margin ratio. From profitability analysis it is found
that all the ratios have fluctuated from time to time. They are in rising trend
up to 2020 but decreases in year 2021, except gross margin ratio. But
fluctuation of net margin is much higher than gross margin. This implies
indirect expenses growth in the study period is much higher. Table-3: Profitability Analysis
Table-4: Principal Component analysis of Profitability
Position
Further from principal component analysis of three
profitability ratios, it is found that as per Kaiser Criterion (KMO-.606) the
principal factor is Gross margin ratio, because Eigen value is more than 1.
From Bartlet Test of Sphericity (BTO) it is found that BTO=6.723 and it is
significant at 1% probability level, which implies Principal Component Analysis
is well fitted here Again, from regression analysis it is found that
operating profit and liquidity are negatively related, though it is
insignificant. Efficiency Analysis: For efficiency analysis in Table-3, it is found that
asset turnover is in rising trend over the study period; in inventory turnover
ratio also, it is in rising trend except last year 2021which may be due to
pandemic Covid-19. In receivable turnover it is in decreasing trend except year
2021. Table-5: Efficiency Analysis:
Table-6: Principal Component analysis of Efficiency
Position
Further from principal component analysis of three
Efficiency ratios, it is found that as per Kaiser Criterion (KMO.455) the
principal factor is Asset Turnover ratio, because Eigen value is more than 1.
From Bartlet Test of Sphericity (BTO) it is found that BTO=9.076 and it is
significant at 5% probability level, which implies Principal Component Analysis
is well fitted here In regression analysis it is found that operating profit
and asset turnover is positively related though insignificant. Capital Structure Analysis: From Table-4 it is found that Debt ratio and debt to
equity ratio had fluctuated from time to time over the study period; but
interest coverage ratio has risen. In each year debt to equity ratio is more
than 50% which implies that the company has taken debt capital advantage to
maximise its return. Also the debt ratio is less than 1 or 100% which means
that the company owns more assets than liabilities and can meet its obligations
by selling its assets if needed so it’s in less risky position. Table-7: Leverage ratios
Table-8: Principal Component analysis of Capital
Structure Position
Further from principal component analysis of three
Efficiency ratios, it is found that as per Kaiser Criterion (KMO.498) the
principal factor is Debt ratio, because Eigen value is more than 1. From
Bartlet Test of Sphericity (BTO) it is found that BTO=21.463 and it is
significant at 1% probability level, which implies Principal Component Analysis
is well fitted here From regression analysis it is found that operating
profit and debt ratio is positively related though insignificant. Market Value Analysis: Table-9: Market value ratios
Table-10: Principal Component analysis of Capital
Structure Position
For market value ratios it is found that except for the second year it is in rising trend over the study period. It is seen that the company is overvalued since its book value is much less than its yearly market value share prices. From Price earnings ratio it is found that they have fluctuated over the period which implies volatility in share price of the company. Earnings per share of the company is negative for the first year but it increased significantly over the years except for year 2021 for which may be because the company was less efficient in that particular year due to the Covid-19 pandemic. Further from principal component analysis of three Market value ratios, it is found that as per Kaiser Criterion (KMO-.518) the principal factor is Debt ratio, because Eigen value is more than 1. From Bartlet Test of Sphericity (BTO) it is found that BTO=4.824, but it is insignificant at 10% probability level, which implies Principal Component Analysis is not well fitted here. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conclusion |
From the above analysis we may conclude that Sun Pharma Ltd. liquidity position had gradually improved, but operating cash flow position to be improved by reduction of non operating expenses, which had impact in Net Profit ratio also; receivable collection should also be increased to improve operating cash flow and net profit margin. Company can take cheaper debt capital facility to improve earnings per share. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Suggestions for the future Study | To improve the overall performance of the company, the suggestions are: 1. Receivable turnover should be increased by emphasis on monitoring of outstanding dues, 2. Indirect expenditure burden should be reduced to raise net profit. 3. Debt-equity ratio may be improved to take cheaper debt capital advantage. 4. Asset turnover ratio should be increased by raising sales volume; because in existing situation it is less than 1. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References | 1. Annual reports of Sun Pharmaceuticals Ltd.
2. Bhunia, A. (2010), “Financial performance of Indian Pharmaceutical Industry- A case study” 'Asian Journal of Management Research' ISSN 2229-3795 pp 427-451
3. Sheela, C. S. &Karthikeyan, K. (2012), “Financial Performance of Pharmaceutical Industry in India Using DuPont Analysis” ‘European Journal of Business and Management’ vol. 4, no. 14, 2012 pp 84-91
4. Altaf, N. & Ahmad, F. (2019), in their article on “Working Capital Financing, Firm Performance and Financial Constraints” published in ‘International Journal of Managerial Finance’ March 2019, pp 1-15
5. Panigrahi, Ashok (2019), in his article on “Analysis of Financial Performance: A Study of Selected Pharmaceutical Companies” published in ‘Global Management Horizon’ Annual Referred Journal 2019, vol. VIII, pp 47-56
6. Priyadharshini & Rajeshwari (2021), in their article on “Analysis of The Profitability and Liquidity Ratios of Pharmaceutical Companies in India” published in ‘EPRA International Journal of Multidisciplinary Research (IJMR) – Peer Reviewed Journal’ vol. 7, issue 7, pp 298-301
7. https://corporatefinanceinstitute.com/resources/knowledge/finance/financial-performance/
8. https://www.moneycontrol.com/ |